Arvinas Inc. (NASDAQ: ARVN) announced results from two Phase 1 clinical trials of ARV-102, an investigational drug designed to treat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE